Carsten Hofmann

2.1k total citations · 1 hit paper
43 papers, 1.3k citations indexed

About

Carsten Hofmann is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Carsten Hofmann has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 11 papers in Molecular Biology and 11 papers in Pharmacology. Recurrent topics in Carsten Hofmann's work include Alzheimer's disease research and treatments (14 papers), Microbial Natural Products and Biosynthesis (8 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Carsten Hofmann is often cited by papers focused on Alzheimer's disease research and treatments (14 papers), Microbial Natural Products and Biosynthesis (8 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Carsten Hofmann collaborates with scholars based in Switzerland, United Kingdom and Germany. Carsten Hofmann's co-authors include M. Jung, Ralf Kießlich, Paul Delmar, Gregory Klein, Paulo Fontoura, Andreas Bechthold, Mirjana Andjelković, Sylvie Retout, Susanne Ostrowitzki and Kaj Blennow and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and NeuroImage.

In The Last Decade

Carsten Hofmann

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

2017 411 citations Susanne Ostrowitzki, Robert Lasser et al. Alzheimer s Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carsten Hofmann Switzerland	17	623	481	356	213	169	43	1.3k
Achiel Van Peer Belgium	19	81 0.1×	215 0.4×	208 0.6×	235 1.1×	111 0.7×	43	1.2k
J. Cory Kalvass United States	22	84 0.1×	176 0.4×	445 1.3×	159 0.7×	128 0.8×	34	1.9k
D. Garceau Canada	15	661 1.1×	349 0.7×	330 0.9×	138 0.6×	174 1.0×	35	1.1k
Trine Meldgaard Lund Denmark	21	322 0.5×	121 0.3×	459 1.3×	72 0.3×	15 0.1×	68	1.3k
Aimée Dallob United States	18	202 0.3×	648 1.3×	210 0.6×	106 0.5×	28 0.2×	27	1.2k
Feng Guo China	23	144 0.2×	121 0.3×	725 2.0×	105 0.5×	77 0.5×	87	1.7k
Shin‐ichiro Nagatsuka Japan	17	278 0.4×	414 0.9×	346 1.0×	183 0.9×	144 0.9×	30	1.2k
Ricardo Lehtonen Rodrigues de Souza Brazil	18	138 0.2×	312 0.6×	399 1.1×	34 0.2×	172 1.0×	75	1.2k
Ronald Schmidt Germany	25	338 0.5×	534 1.1×	614 1.7×	91 0.4×	12 0.1×	40	2.2k
Deepak Bhatt United States	19	168 0.3×	117 0.2×	267 0.8×	232 1.1×	33 0.2×	31	1.0k

Countries citing papers authored by Carsten Hofmann

Since Specialization

Citations

This map shows the geographic impact of Carsten Hofmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Hofmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Hofmann more than expected).

Fields of papers citing papers by Carsten Hofmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Hofmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Hofmann. The network helps show where Carsten Hofmann may publish in the future.

Co-authorship network of co-authors of Carsten Hofmann

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Hofmann. A scholar is included among the top collaborators of Carsten Hofmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Hofmann. Carsten Hofmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klein, Gregory, Tobias Bittner, Daria Rukina, et al.. (2025). Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease. Alzheimer s & Dementia. 21(S5). e104288–e104288.

Kulic, Luka, Gregory Klein, Carsten Hofmann, et al.. (2025). Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s disease. Alzheimer s & Dementia. 21(S5). e104293–e104293.

Boada, Merçé, Szofia Bullain, Tobias Bittner, et al.. (2024). Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). Journal of Alzheimer s Disease. 103(2). 528–541.

Boess, Frank, Marzia A. Scelsi, Timo Grimmer, et al.. (2024). At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. The Journal of Prevention of Alzheimer s Disease. 11(3). 537–548. 1 indexed citations

Aldea, Roxana, Hans Peter Grimm, Ronald Gieschke, et al.. (2022). In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model. Alzheimer s & Dementia Translational Research & Clinical Interventions. 8(1). e12306–e12306. 10 indexed citations

Klein, Gregory, Paul Delmar, Geoffrey A. Kerchner, et al.. (2021). Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. The Journal of Prevention of Alzheimer s Disease. 8(1). 3–6. 44 indexed citations

Bogman, Katrijn, Jochen Brumm, Carsten Hofmann, et al.. (2019). Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clinical Pharmacokinetics. 58(9). 1205–1214. 2 indexed citations

Portron, Agnès, et al.. (2019). A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers. Clinical Therapeutics. 42(1). 108–120.e1. 33 indexed citations

Klein, Gregory, Paul Delmar, Carsten Hofmann, et al.. (2018). Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005). Neurology. 90(15_supplement). 3 indexed citations

10.

Ostrowitzki, Susanne, Robert Lasser, Ernest Dorflinger, et al.. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer s Research & Therapy. 9(1). 95–95. 411 indexed citations breakdown →

11.

Hofmann, Carsten, Christophe Boetsch, Daniela Alberati, et al.. (2016). Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers. Psychopharmacology. 233(13). 2429–2439. 21 indexed citations

12.

Boetsch, Christophe, Neil Parrott, Stephen Fowler, et al.. (2015). Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. Clinical Pharmacokinetics. 55(2). 237–247. 11 indexed citations

13.

Parrott, Neil, Dominik Hainzl, Daniela Alberati, et al.. (2013). Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics. 52(8). 673–683. 15 indexed citations

14.

Hofmann, Carsten, et al.. (2012). Evaluation of the Effects of Bitopertin (RG1678) on Cardiac Repolarization: A Thorough Corrected QT Study in Healthy Male Volunteers. Clinical Therapeutics. 34(10). 2061–2071. 13 indexed citations

15.

Wong, Dean F., Susanne Ostrowitzki, Yun Zhou, et al.. (2011). Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage. 75. 282–290. 17 indexed citations

16.

Bechthold, Andreas, Gabriele Weitnauer, Andriy Luzhetskyy, et al.. (2006). Glycosyltransferases and Other Tailoring Enzymes as Tools for the Generation of Novel Compounds. PubMed. 147–163.

17.

Hofmann, Carsten, Berit L. Heitmann, Clemens Dürr, et al.. (2005). Genes Encoding Enzymes Responsible for Biosynthesis of L-Lyxose and Attachment of Eurekanate during Avilamycin Biosynthesis. Chemistry & Biology. 12(10). 1137–1143. 42 indexed citations

18.

Luzhetskyy, Andriy, Li Zhu, Miranda Gibson, et al.. (2005). Generation of Novel Landomycins M and O through Targeted Gene Disruption. ChemBioChem. 6(4). 675–678. 38 indexed citations

19.

Weitnauer, Gabriele, et al.. (2004). Novel Avilamycin Derivatives with Improved Polarity Generated by Targeted Gene Disruption. Chemistry & Biology. 11(10). 1403–1411. 31 indexed citations

20.

Hofmann, Carsten, et al.. (1999). [Propofol for sedation in gastroscopy--a randomized comparison with midazolam].. PubMed. 37(7). 589–95. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact